Please wait while we load the requested 10-Q report or click the link below:
Voyager Therapeutics Reports Second Quarter 2017 Financial Results and Corporate Highlights
Lead program VY-AADC for advanced Parkinson’s disease progressing towards pivotal trials
Cambridge, Mass., August 8, 2017 – Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today reported its second quarter of 2017 financial results and corporate highlights.
“The second quarter of 2017 was a very productive period for our company,” said Steve Paul, M.D., president and chief executive officer of Voyager Therapeutics. “Our Parkinson’s disease program continues to advance as we optimize dose and delivery before initiating our pivotal program later this year. Our preclinical pipeline programs also made solid progress toward entering the clinic. In addition, work with our collaborators to further optimize AAV capsids demonstrated exciting progress, including enhanced gene transfer to the brain and spinal cord in preclinical models compared to the historical standard, AAV9. During the quarter, we also made a number of key hires to strengthen our leadership team and solidify our position as the leading gene therapy company focused on severe neurological diseases.”
Recent Program Highlights
VY-AADC for advanced Parkinson’s disease:
Successfully administered VY-AADC01 to the first patient in a Phase 1 trial with a posterior surgical delivery approach. This posterior (i.e., back of the head) delivery approach aims to further optimize the surgical delivery of VY-AADC01 for advanced Parkinson’s disease. A posterior approach into the putamen, the specific region of the brain targeted by Voyager’s gene therapy program, could better align the delivery of VY-AADC01 with the anatomical structure of the putamen to potentially reduce the total procedure time and further increase the total coverage of the putamen. The administration of VY-AADC01 with this posterior approach was well-tolerated and no serious adverse events were reported. Similar to many patients in the Phase 1b trial, this patient was discharged from the hospital one day after surgery. Additional patients completed screening and will enroll shortly. Preliminary total procedure time and putaminal coverage data from this posterior trajectory trial will help inform the design of the pivotal Phase 2-3 program planned to initiate during late 2017.
The following information was filed by Voyager Therapeutics, Inc. (VYGR) on Tuesday, August 8, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Voyager Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Voyager Therapeutics, Inc..